Datasets and Gene Set

Gene expression and clinical data of eight public ovarian cancer datasets ({"type":"entrez-geo","attrs":{"text":"GSE2109","term_id":"2109"}}GSE2109, {"type":"entrez-geo","attrs":{"text":"GSE9891","term_id":"9891"}}GSE9891, {"type":"entrez-geo","attrs":{"text":"GSE18520","term_id":"18520"}}GSE18520, {"type":"entrez-geo","attrs":{"text":"GSE19829","term_id":"19829"}}GSE19829, {"type":"entrez-geo","attrs":{"text":"GSE20565","term_id":"20565"}}GSE20565, {"type":"entrez-geo","attrs":{"text":"GSE26193","term_id":"26193"}}GSE26193, {"type":"entrez-geo","attrs":{"text":"GSE30161","term_id":"30161"}}GSE30161, and {"type":"entrez-geo","attrs":{"text":"GSE44104","term_id":"44104"}}GSE44104) measured by Affymetrix HG-U133A 2.0 were extracted from the R curatedOvarianData Bioconductor package (19–25). After removal of healthy people, 907 ovarian cancer patients were enrolled in this study. We analyzed 30 CTLA-4-related genes, 9 PD-1/PD-L1-related genes, 6 genes related to both, and 3 CL-related genes. Genes related to anti-CTLA-4 therapy were CTLA-4, PD-L2, GZMA, and PRF1, as reported by Van Allen et al. (13). Genes related to anti-PD-1/PD-L1 therapy were PD-L1, CD8A, GZMA, and PRF1, as reported by Ock et al. and Chen et al. (14, 15). TCGA RNA-Seq data were used as independent validation cohort, which included 261 serous ovarian cancer patients.